Carnosine supplement and walking ability in people with peripheral arterial disease
Tests carnosine supplements for walking ability in people with peripheral arterial disease.
Key facts
- Who runs it
- Shahid Baba
- Where
- Louisville, United StatesSee the 3 sites
- Trial code
- Registry title
- Effects of Carnosine In Patients With Peripheral Arterial Disease Patients
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 144 people, planned
- Started
- 20 May 2025
- Expected to end
- 1 Oct 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Carnosine
- Record updated
- 29 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 to 80 with peripheral arterial disease (narrowed leg arteries), with or without leg pain when walking. It tests whether carnosine 2 g daily for 6 months improves walking.
- Age
- 40 to 80 years
- Sex
- All sexes
- Disease stage
- Peripheral arterial disease with an ABI (ankle-arm blood pressure ratio) above 0.4 and below 0.90. A 6-minute walk test result between 152.0 meters (498ft) and 487.7 meters (1600ft).
- Earlier treatment
- No vascular procedure on the affected leg in the 6 months before joining. Cannot already take carnosine or have been in any carnosine trial before.
- Biomarker or test result
- ABI >0.4-<0.90, measured within 6 weeks before joining.
Main reasons for not taking part
- Severe loss of blood flow to the leg with amputation or a foot sore on the affected leg
- Pregnancy
- Known allergy to L-carnosine, or carnosinemia or carnosinase deficiency
- Unable to give a urine sample, or taking part in another clinical trial
- At the doctor's choice: HIV, hepatitis, serious liver disease, anemia, dialysis, home oxygen, or active cancer
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Participants between 40-80 years of age
- White or African American race
- Literate in English
- ABI >0.4-<0.90, obtained within 6 weeks from enrollment
- Willing and able to comply with protocol requirements
- Participant is able to provide informed consent
Who cannot take part
- Presence of significant injury within 30 days, or vascular intervention on the symptomatic leg within 6 months before enrollment, as per physician's discretion
- Participants using dual antiplatelet therapies will not be included for biopsy
- As per physician's discretion, participants with HIV, hepatitis, significant liver disease, anemia, renal disease requiring dialysis, lung disease requiring home oxygen therapy, and active cancer may be excluded
- Known allergy to L-carnosine
- Participants with rare autosomal recessive metabolic disorder carnosinemia or carnosinase deficiency
- Critical limb ischemia with below or above the knee amputations or any form of foot ulceration over the symptomatic leg
- Participants with a baseline 6MWT of less than 152.0 meters (498ft) or greater than 487.7 meters (1600ft)
- Currently participating in other clinical trials
- Participation in any carnosine supplementation clinical trial anytime in the past
- Participants already taking carnosine
- Participants unable to provide urine sample (anuric)
- Pregnant participants
- Participants with internal metallic objects in body will not be eligible for MRI or 1HMRS
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Where in United States
- University of Louisville School of Medicine, Department of Medicine, Division of Environmental MedicineLouisville, United StatesContact: Shahid Baba, PhDTaking people
- University Surgical Associates, 401 E. Chestnut St, Suite 710Louisville, United StatesContact: Shahid Baba, PhDNot yet recruiting
- UofL Physicians - Vascular Surgery Associates, 201 Abraham Flexner Way, Suite 1004Louisville, United StatesContact: Shahid Baba, PhDNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to determine whether carnosine (a food ingredient found in chicken and red meat) supplementation (2 g) for 6 months in participants with non-claudication and claudication peripheral arterial disease (PAD) improves walking ability. Previous studies with heart failure patients have shown that carnosine supplementation increases walking capacity in these patients.
The 2 groups in the trial
- PlaceboNo study treatment, for comparison
Cellulose
- CarnosineTreatment being tested
Carnosine 2 g daily for 6 months
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effects of Carnosine In Patients With Peripheral Arterial Disease Patients; Randomized Intervention Trial (CIPHER)
- Plain-language title
- Carnosine supplement and walking ability in people with peripheral arterial diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06480760, who can take part
- Record updated
- 29 May 2025